Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.

COVID-19, other infections linked to major cardiovascular risks—researchers push for vaccination
Adults are three times as likely to have a heart attack or stroke after a COVID-19 infection than when they are healthy. The risks are even greater for the flu.
How to minimize bleeding risks after TAVR
Bleeding events remain a serious complication after TAVR. By identifying high-risk patients early and planning ahead, however, care teams can keep them to a minimum.
Novo Nordisk, Pfizer enter bidding war for biotech startup—and it is getting ugly
Pfizer was all set to acquire New York City-based Metsera for $4.9 billion, but Novo Nordisk stepped in with an unexpected counteroffer of $6.5 billion. Both companies hope to add Metsera's drugs to their GLP-1 portfolios.
Private equity-backed Medline files for IPO
The company, founded in 1966, has been providing supplies to cardiac surgery suites and cath labs for decades.
Key takeaways for interventional cardiology from TCT 2025
B. Hadley Wilson, MD, talked to Cardiovascular Business about several standout late-breaking clinical trials presented at TCT 2025. Topics of those trials included drug-coated balloons, TAVR valve durability, pulmonary embolism treatments and much more.

Permanent pacemakers after TAVR: Tracking the impact of modern self-expanding valves

Researchers explored data from more than 3,000 TAVR patients, presenting their results in JACC: Cardiovascular Interventions.

New research suggests immunotherapy for AFib could be on the horizon

Targeting immune cells that play a key role in the development of atrial fibrillation could give cardiologists a new way to treat the disease.

K-Clip annuloplasty system for tricuspid regurgitation by Shanghai Huihe Medical Technology Co.

Cardiologists detail world's first use of new annuloplasty system for tricuspid regurgitation

Early data suggest the new transcatheter tricuspid valve repair device could make a big impact on patient care, but additional research is still necessary.

PROMISE trial results reinforce confidence in new MRI contrast agent

The randomized, double-blinded phase 3 study revealed gadopiclenol to be noninferior to gadobutrol for all qualitative visualization parameters as rated by all blinded readers involved in the trial.

FDA provides next steps in wake of blood test recall

According to the FDA, a limited number of unaffected blood tests are available if providers are unable to identify a better way forward.

Image of a bioprosthetic valve within the RVOT from the SCCT's congenital heart disease guidelines

SCCT shares new recommendations on use of CT imaging to guide congenital heart disease treatment

The group collaborated with two other medical societies, SCAI and CHSS, on the expert consensus document.

VDyne Valve for transcatheter tricuspid valve replacement

Cardiologists highlight early success of new TTVR system for tricuspid regurgitation

Results from a first-in-human study suggest this new-look device could provide cardiologists and their care teams with another way to treat tricuspid regurgitation in high-risk patients.

Medtronic recalls nearly 350,000 implantable heart devices after 22 injuries

The FDA has categorized this as a Class I recall, meaning the use of these devices could cause “serious injuries or death.”

Clinical

COVID-19, other infections linked to major cardiovascular risks—researchers push for vaccination

How to minimize bleeding risks after TAVR

Novo Nordisk, Pfizer enter bidding war for biotech startup—and it is getting ugly

Private equity-backed Medline files for IPO

Key takeaways for interventional cardiology from TCT 2025